Cosmo Bio Company,Limited

3386

JP3298700000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1,044 ^JPY	0.00%		+1.95%	+6.21%

2023	Cosmo Bio Company,Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2023	Cosmo Bio Company,Limited Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Cosmo Bio Company,Limited Reports Earnings Results for the First Quarter Ended March 31, 2023

May 10, 2023 at 02:00 am

Cosmo Bio Company,Limited reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was JPY 2,828 million. Net income was JPY 264 million.

Basic earnings per share from continuing operations was JPY 45.46.

Latest news about Cosmo Bio Company,Limited

Cosmo Bio Company,Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Cosmo Bio Company,Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
Tranche Update on Cosmo Bio Company,Limited's Equity Buyback Plan announced on February 12, 2021.	21-07-13	CI
Cosmo Bio Company,Limited's Equity Buyback announced on February 12, 2021, has closed with 160,000 shares, representing 2.71% for ¥194.04 million.	21-07-11	CI
Tranche Update on Cosmo Bio Company,Limited's Equity Buyback Plan announced on February 12, 2021.	21-07-01	CI
Tranche Update on Cosmo Bio Company,Limited's Equity Buyback Plan announced on February 12, 2021.	21-04-01	CI
Cosmo Bio Company,Limited announces an Equity Buyback for 160,000, representing 2.7% of its issued share capital shares, for ¥200 million.	21-02-12	CI
Cosmo Bio Company,Limited authorizes a Buyback Plan.	21-02-11	CI
MeSCue-Janusys Inc. announced that it has received ¥50 million in funding from Cosmo Bio Company,Limited	19-04-16	CI
MeSCue-Janusys Inc. announced that it expects to receive ¥50 million in funding from Cosmo Bio Company,Limited and other investors	19-04-09	CI
FIMECS, Inc. announced that it has received $2.3 million in funding from Takeda Pharmaceutical Company Limited, Cosmo Bio Company,Limited	18-04-09	CI
Canopy Biosciences, LLC Announces Distribution Agreement with Cosmo Bio Co., Ltd. for Japan Life Science Market	17-06-22	CI
C-LEcta Signs Sales and Distribution Agreement with Cosmo Bio Co., Ltd. for Japan	17-06-06	CI
Organovo Holdings Signs Exclusive Distributor Agreement with Cosmo Bio Co., Ltd	16-12-14	CI
SOLA Biosciences LLC Announces Distribution Agreement with Cosmo Bio Co., LTD	16-09-27	CI
Avacta Group plc Names Cosmo Bio Co Ltd as Distributor in Japan for Affimers	14-07-15	CI
Enzo Life Sciences, Inc. Expands Distribution Agreement with Cosmo Bio Co. Ltd	12-03-20	CI

Chart Cosmo Bio Company,Limited

Duration

Period

More charts

Company Profile

COSMO BIO COMPANY,LIMITED is a Japan-based company mainly engaged in purchase and wholesale of research reagents, equipment, consignment services and clinical test drugs related to life science. Research reagents business imports majority research reagents from United States and Europe, which are prioritized in life science related research. In the equipment business, the Company handles equipment specialized in life science research, purchases goods from a wide range of domestic and overseas, and mainly sells it to the domestic market. The equipment includes ultrasonic cell disruption equipment, bioimaging related equipment and research consumables. The Company provides clinical test drugs mainly used at hospitals and testing centers.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company